Peer Review reports
From: Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
| Original Submission | ||
|---|---|---|
| 29 Jun 2015 | Submitted | Original manuscript |
| 17 Aug 2015 | Reviewed | Reviewer Report - Vimla Band |
| 11 Dec 2015 | Reviewed | Reviewer Report - SHEVDE SAMANT |
| 22 Mar 2016 | Author responded | Author comments - Marc Becker |
| Resubmission - Version 2 | ||
| 22 Mar 2016 | Submitted | Manuscript version 2 |
| 13 Apr 2016 | Reviewed | Reviewer Report - Vimla Band |
| 3 May 2016 | Reviewed | Reviewer Report - Gargi Ghosal |
| 2 Jul 2016 | Author responded | Author comments - Marc Becker |
| Resubmission - Version 3 | ||
| 2 Jul 2016 | Submitted | Manuscript version 3 |
| 20 Jul 2016 | Reviewed | Reviewer Report - Gargi Ghosal |
| 21 Jul 2016 | Author responded | Author comments - Marc Becker |
| Resubmission - Version 4 | ||
| 21 Jul 2016 | Submitted | Manuscript version 4 |
| Publishing | ||
| 7 Oct 2016 | Editorially accepted | |
| 20 Oct 2016 | Article published | 10.1186/s12885-016-2847-3 |
You can find further information about peer review here.